Citations 2
The New NCI Precision Medicine Trials
Harris, Lyndsay N. , Blanke, Charles D. , Erba, Harry P. , Ford, James M. , Gray, Robert J. , LeBlanc, Michael , Hu‐Lieskovan, Siwen , Litzow, Mark R. , Luger, Selina M. , Meric‐Bernstam, Funda , O’Dwyer, Peter J. , Politi, Katerina , Shepherd, Lois E. , Allegra, Carmen J. , Korde, Larissa A. , Little, Richard F. , Moscow, Jeffrey A. , Thurin, Magdalena , Doroshow, James H. , LeBlanc, Michael L , Othus, Megan , Politi, Katerina , Shepherd, LE , Allegra, Carmen J , Chen, Helen X , Ivy, S. Percy , Korde, Larissa A , Little, Richard F , McShane, Lisa M. , Moscow, Jeffrey A , Patton, David R , Thurin, Magdalena , Yee, Laura M , Doroshow, James H , Erba, Harry Paul , Meric-Bernstam, Funda , Gray, Robert J , Patton, David R.
Clinical Cancer Research | August 2, 2023 | Volume: 29 | Issue: 23 | Pages: 4728-4732
Abstract Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First-generation trials like NCI-MATCH (Molecular Analysis for Therapy Choice) have proven the principle that studying targeted therapies on a large scale is feasible both from the laboratory and clinical perspectives. However, single-agent targeted therapies have shown limited ability to control metastatic disease, despite careful matching of drug to target. As such, newer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI has recently embarked on three second-generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.
Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma
Tricoli, James V. , Blair, Donald G., Anders, Carey K. , Bleyer, W. Archie, Boardman, Lisa A., Khan, Javed , Hayes‐Lattin, Brandon , Merchant, Melinda S., Seibel, Nita L. , Thurin, Magdalena , Boardman, Lisa A., Kummar, Shivaani , Hunger, Stephen P. , Willman, Cheryl L.
Cancer | February 5, 2016 | Volume: 122 | Issue: 7 | Pages: 1017-1028
Adolescent and young adult (AYA) patients with cancer have not attained the same improvements in overall survival as either younger children or older adults. One possible reason for this disparity may be that the AYA cancers exhibit unique biologic characteristics, resulting in differences in clinical and treatment resistance behaviors. This report from the biologic component of the jointly sponsored National Cancer Institute and LiveStrong Foundation workshop entitled “Next Steps in Adolescent and Young Adult Oncology” summarizes the current status of biologic and translational research progress for 5 AYA cancers; colorectal cancer breast cancer, acute lymphoblastic leukemia, melanoma, and sarcoma. Conclusions from this meeting included the need for basic biologic, genomic, and model development for AYA cancers as well as translational research studies to elucidate any fundamental differences between pediatric, AYA, and adult cancers. The biologic questions for future research are whether there are mutational or signaling pathway differences (for example, between adult and AYA colorectal cancer) that can be clinically exploited to develop novel therapies for treating AYA cancers and to develop companion diagnostics. Cancer 2016;122:1017–1028. © 2016 American Cancer Society